AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...

Financially, Monopar has a cash runway until 2026 but will need additional funds for commercialization efforts. See why I'm ...

Shares of AstraZeneca PLC (LON:AZN – Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of £114.30 ($145.26) and traded as high ...